ICAM1-Targeting Theranostic Nanoparticles for Magnetic Resonance Imaging and Therapy of Triple-Negative Breast Cancer

Chen, Jieying; Lv, Mingchen; Su, Xiaolian; Wang, Sizhu; Wang, Yitong; Fan, Zhen; Zhang, Lin; Tang, Guangyu

doi:10.2147/ijn.s374293

Cited by 7 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Theranostic nanoparticles modified with anti-ICAM1 target could specifically target TNBC in an in vitro experiment by Chen et al. ( 53 ). However, a recent study found that ICAM1-deficient breast cancer cells develop large metastatic lesions ( 54 ).…”

Section: Discussionmentioning

confidence: 99%

Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer

Zhou,

Xu,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundTreating triple-negative breast cancer (TNBC) is a difficult landscape owing to its short survival times and high risk of metastasis and recurrence among patients. Although involved in tumor invasion and metastasis, the mechanism of action of intercellular adhesion molecule 1 (ICAM1), a trans-membrane glycoprotein, in TNBC is ambiguous.MethodsWe examined ICAM1’s role in TNBC, focusing on its expression, cell survival, mutation, and tumor immunity. Then, a risk score model was created utilizing co-expressed genes associated with ICAM1. According to their respective risk scores, we divided patients into high- and low-risk groups. Immune function, drug susceptibility differences, and somatic variants were analyzed in the high-and low-risk groups. And we used the CMap database to predict potential medications. Then, TNBC cells with low expression of ICAM-1 were co-cultured with PMA-treated THP-1 cells and CD8 T cells. In addition, We detected the expression of PD-1 and CTLA4 of low ICAM-1 expressing TNBC cells when they were cocultured with CD8 T cells.ResultsICAM1 was found to be involved in leukocyte cell adhesion, motility, and immune activation. Patients with low-ICAM1 group had shorter disease-free survival (DFS) than those with high-ICAM1 group. The group with elevated levels of ICAM1 exhibited significantly increased levels of T-cell regulation, quiescence in natural killer (NK) cells, and M1 macrophage. ICAM1 expression was correlated with immune checkpoint drugs. The prognostic ability of the risk score model was found to be superior to that of individual genes. Patients categorized as high-risk exhibited elevated clinical stages, showed higher M1 macrophage numbers, and were able to benefit better from immunotherapy. Individuals belonging to the high-risk group exhibit significantly elevated mutation rates in TP53, TTN, and SYNE1 genes, along with increased TMB and PD-L1 levels and decreased TIDE scores. These findings suggest that immunotherapy may be advantageous for the high-risk group. Furthermore, low expression of ICAM1 was found to promote polarization to M2 macrophages along with T-cell exhaustion.ConclusionIn conclusion, Low ICAM1 expression may be related to immune escape, leading to poor treatment response and a worse prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer

Zhou,

Xu,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…To address this issue, vesicular NPs with poly(ethylene glycol)-poly(ε-caprolactone) copolymers conjugate anti-ICAM1 antibodies using click chemistry. These NPs have shown enhanced diagnostic and therapeutic efficacy in tumor models, with extended circulation time, and additionally in vitro experiments exhibited specific targeting action specifically for TNBC . Theranostic NPs offer multiple therapeutic applications, including tumor-targeting imaging, focused ultrasound ablation, chemotherapy, and sonodynamic therapy.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

“…These NPs have shown enhanced diagnostic and therapeutic efficacy in tumor models, with extended circulation time, and additionally in vitro experiments exhibited specific targeting action specifically for TNBC. 134 Theranostic NPs offer multiple therapeutic applications, including tumor-targeting imaging, focused ultrasound ablation, chemotherapy, and sonodynamic therapy. A multimodal synergistic therapy can enhance TNBC treatment efficacy and prognosis by enhancing imaging, guided ablation, and focused ultrasound (FUS)/chemotherapy effects.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Breast cancer (BC) is a malignant neoplasm that begins in the breast tissue. After skin cancer, BC is the second most common type of cancer in women. At the end of 2040, the number of newly diagnosed BC cases is projected to increase by over 40%, reaching approximately 3 million worldwide annually. The hormonal and chemotherapeutic approaches based on conventional formulations have inappropriate therapeutic effects and suboptimal pharmacokinetic responses with nonspecific targeting actions. To overcome such issues, the use of nanomedicines, including liposomes, nanoparticles, micelles, hybrid nanoparticles, etc., has gained wider attention in the treatment of BC. Smaller dimensional nanomedicine (especially 50–200 nm) exhibited improved in vivo effectiveness, such as better tissue penetration and more effective tumor suppression through enhanced retention and permeation, as well as active targeting of the drug. Additionally, nanotechnology, which further extended and developed theranostic nanomedicine by incorporating diagnostic and imaging agents in one platform, has been applied to BC. Furthermore, hybrid and theranostic nanomedicine has also been explored for gene delivery as anticancer therapeutics in BC. Moreover, the nanocarriers’ size, shape, surface charge, chemical compositions, and surface area play an important role in the nanocarriers’ stability, cellular absorption, cytotoxicity, cellular uptake, and toxicity. Additionally, nanomedicine clinical translation for managing BC remains a slow process. However, a few cases are being used clinically, and their progress with the current challenges is addressed in this Review. Therefore, this Review extensively discusses recent advancements in nanomedicine and its clinical challenges in BC.

show abstract

“…Because only 1% of the intravenously injected nanomaterials could enter the tumour through the EPR (enhanced permeability and retention) effect, [39][40][41] we injected the nanomaterials directly into the tumour in order to achieve better imaging results. 42,43 Eu 3+ @L-Arg nanomaterials (62.5 mg mL −1 , 50 mL) were injected into the tumours of TUBO and 4T1 at day 5, 10 and 15 aer implantation of tumour cells. T2 and CEST scanning were undertook before and aer the injection.…”

Section: Cest Imaging Ability Of Eu 3+ @L-arg In Vivomentioning

confidence: 99%